Medicines Co. still fighting for Angiomax patent

In spite of a third rejection from the U.S. Patent Office, Medicines Co. CEO Clive Meanwell says he will pursue all options to extend its exclusive rights to the anticoagulant drug Angiomax that accounts for 95 percent of the company's revenue. Report